Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02632409 · ClinicalTrials.gov registry record · Phase 3
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
A Phase 3 study of Various Advanced Cancer, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 709
- Enrollment target
- 20
- Study locations
NCT02632409: Active Phase 3 study of Various Advanced Cancer, sponsored by Bristol-Myers Squibb.
NCT02632409 is a Phase 3 study of Various Advanced Cancer that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 709 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02632409, a Phase 3 study of Various Advanced Cancer, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 709 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
Primary Outcome
The time between the date of randomization and the date of first documented recurrence (local urothelial tract, local non-urothelial tract or distant), or death due to any cause, whichever occurs first.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Nivolumab
Study Locations (20)
California
- Local Institution - 0061 - Clovis
- Local Institution - 0172 - Sacramento
- Local Institution - 0005 - San Francisco
Florida
- Local Institution - 0167 - Gainesville
- Local Institution - 0030 - Miami Beach
- Local Institution - 0008 - Tampa
New York
- Local Institution - 0176 - Albany
- Local Institution - 0157 - Buffalo
- Local Institution - 0007 - Mineola
Minnesota
- Local Institution - 0051 - Burnsville
- Local Institution - 0004 - Rochester
Alaska
- Alaska Urological Institute dba Alaska Clinical Research Center - Anchorage
Arizona
- Local Institution - 0179 - Tucson
Colorado
- Local Institution - 0178 - Lakewood
Illinois
- Local Institution - 0168 - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 709 participants |
| Start Date | 2016-03-22 |
| Est. Completion | 2027-05-27 |
| Phase | Phase 3 |
What the registry record for NCT02632409 still lists
NCT02632409 is an interventional study that assigns participants to a tested intervention. The registered 709 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 1 condition, with Various Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02632409 names 20 study sites across 13 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT02632409 about?
NCT02632409 is a clinical study titled "An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer". The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
What is the current status of trial NCT02632409?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 709 participants. The study started on 2016-03-22. Estimated completion is 2027-05-27.
What conditions does trial NCT02632409 study?
This clinical trial studies the following conditions: Various Advanced Cancer.
What interventions are being tested in trial NCT02632409?
The interventions under investigation include: Placebo (OTHER), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02632409?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02632409 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02632409's enrollment target sits among peer trials
709 505th of 2000 higher than 1,496 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI